|
1
|
Zhu N, Zhang D, Wang W, Li X, Yang B, Song
J, Zhao X, Huang B, Shi W, Lu R, et al: A novel coronavirus from
patients with pneumonia in China, 2019. N. Engl J Med. 382:727–733.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Horton R: Offline: COVID-19 is not a
pandemic. Lancet. 396(935)2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Musumeci G: Effects of COVID-19 Syndemic
on Sport Community. J Funct Morphol Kinesiol. 7(19)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ministero della Salute. Covid-19,
situation in Italy. https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?area=nuovoCoronavirus&id=5367&lingua=english&menu=vuoto.
Accessed February 24, 2022.
|
|
5
|
Osuchowski MF, Winkler MS, Skirecki T,
Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer
M, Brunkhorst FM, et al: The COVID-19 puzzle: Deciphering
pathophysiology and phenotypes of a new disease entity. Lancet
Respir Med. 9:622–642. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Grasselli G, Tonetti T, Protti A, Langer
T, Girardis M, Bellani G, Laffey J, Carrafiello G, Carsana L,
Rizzuto C, et al: Pathophysiology of COVID-19-associated acute
respiratory distress syndrome: A multicentre prospective
observational study. Lancet Respir Med. 8:1201–1208.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
RECOVERY Collaborative Group. Horby P, Lim
WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N,
Brightling C, Ustianowski A, et al: Dexamethasone in Hospitalized
patients with Covid-19. N Engl J Med. 384:693–704. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Nissen CB, Sciascia S, de Andrade D,
Atsumi T, Bruce IN, Cron RQ, Hendricks O, Roccatello D, Stach K,
Trunfio M, et al: The role of antirheumatics in patients with
COVID-19. Lancet Rheumatol. 3:e447–e459. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Angriman F, Ferreyro BL, Burry L, Fan E,
Ferguson ND, Husain S, Keshavjee SH, Lupia E, Munshi L, Renzi S, et
al: Interleukin-6 receptor blockade in patients with COVID-19:
Placing clinical trials into context. Lancet Respir Med. 9:655–664.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bhimraj A, Morgan R, Shumaker A, Lavergne
V, Baden L, Cheng VC-C, Edwards KM, Gandhi R, Gallagher J, Muller
WJ, et al: IDSA Guidelines on the treatment and management of
patients with COVID-19. Published by IDSA on 4/11/2020. Last
updated, 3/23/2022. Available: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/.
|
|
11
|
Bassetti M, Giacobbe DR, Bruzzi P,
Barisione E, Centanni S, Castaldo N, Corcione S, De Rosa FG, Di
Marco F, Gori A, et al: Clinical management of adult patients with
COVID-19 outside intensive care units: Guidelines from the Italian
society of anti-infective therapy (SITA) and the Italian Society of
Pulmonology (SIP). Infect Dis Ther. 10:1837–1885. 2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lescure FX, Honda H, Fowler RA, Lazar JS,
Shi G, Wung P, Patel N and Hagino O: Sarilumab COVID-19 Global
Study Group. Sarilumab in patients admitted to hospital with severe
or critical COVID-19: A randomised, double-blind,
placebo-controlled, phase 3 trial. Lancet Respir Med. 9:522–532.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zizzo G, Tamburello A, Castelnovo L, Laria
A, Mumoli N, Faggioli PM, Stefani I and Mazzone A: Immunotherapy of
COVID-19: Inside and beyond IL-6 signalling. Front Immunol.
13(795315)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bhimraj A, Morgan RL, Shumaker AH,
Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi R, Gallagher J,
Muller WJ, et al: Infectious Diseases Society of America Guidelines
on the treatment and management of patients with COVID-19. Clin
Infect Dis: Apr 27, 2020 (Epub ahead of print). doi:
10.1093/cid/ciaa478.
|
|
15
|
Nunnari G, Sanfilippo C, Castrogiovanni P,
Imbesi R, Li Volti G, Barbagallo I, Musumeci G and Di Rosa M:
Network perturbation analysis in human bronchial epithelial cells
following SARS-CoV2 infection. Exp Cell Res.
395(112204)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Que Y, Hu C, Wan K, Hu P, Wang R, Luo J,
Li T, Ping R, Hu Q, Sun Y, et al: Cytokine release syndrome in
COVID-19: A major mechanism of morbidity and mortality. Int Rev
Immunol. 41:217–230. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cosentino F, Moscatt V, Marino A,
Pampaloni A, Scuderi D, Ceccarelli M, Benanti F, Gussio M, Larocca
L, Boscia V, et al: Clinical characteristics and predictors of
death among hospitalized patients infected with SARS-CoV-2 in
Sicily, Italy: A retrospective observational study. Biomed Rep.
16(34)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Della-Torre E, Campochiaro C, Cavalli G,
De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di
Terlizzi G, Lanzillotta M, et al: Interleukin-6 blockade with
sarilumab in severe COVID-19 pneumonia with systemic
hyperinflammation: An open-label cohort study. Ann Rheum Dis.
79:1277–1285. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gremese E, Cingolani A, Bosello SL,
Alivernini S, Tolusso B, Perniola S, Landi F, Pompili M, Murri R,
Santoliquido A, et al: Sarilumab use in severe SARS-CoV-2
pneumonia. EClinicalMedicine. 27(100553)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Benucci M, Giannasi G, Cecchini P, Gobbi
FL, Damiani A, Grossi V, Infantino M and Manfredi M: COVID-19
pneumonia treated with Sarilumab: A clinical series of eight
patients. J Med Virol. 92:2368–2370. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
REMAP-CAP Investigators. Gordon AC,
Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D,
Beane A, van Bentum-Puijk W, et al: Interleukin-6 receptor
antagonists in Critically Ill patients with Covid-19. N Engl J Med.
384:1491–1502. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
CORIMUNO-19 Collaborative group. Sarilumab
in adults hospitalised with moderate-to-severe COVID-19 pneumonia
(CORIMUNO-SARI-1): An open-label randomised controlled trial.
Lancet Rheumatol. 4:e24–e32. 2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Marino A, Pampaloni A, Scuderi D,
Cosentino F, Moscatt V, Ceccarelli M, Gussio M, Celesia BM, Bruno
R, Borraccino S, et al: High-flow nasal cannula oxygenation and
tocilizumab administration in patients critically ill with
COVID-19: A report of three cases and a literature review. World
Acad Sci J. 2(1)2020.
|
|
24
|
Ceccarelli M, Marino A, Cosentino F,
Moscatt V, Celesia BM, Gussio M, Bruno R, Rullo EV, Nunnari G and
Cacopardo BS: Post-infectious ST elevation myocardial infarction
following a COVID-19 infection: A case report. Biomed Rep.
16(10)2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Marino A, Cosentino F, Ceccarelli M,
Moscatt V, Pampaloni A, Scuderi D, D'Andrea F, Rullo EV, Nunnari G,
Benanti F, et al: Entecavir resistance in a patient with
treatment-naïve HBV: A case report. Mol Clin Oncol.
14(113)2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Celesia BM, Marino A, Borracino S,
Arcadipane AF, Pantò G, Gussio M, Coniglio S, Pennisi A, Cacopardo
B and Panarello G: Successful extracorporeal membrane oxygenation
treatment in an acquired immune deficiency syndrome (AIDS) patient
with acute respiratory distress syndrome (ARDS) complicating
pneumocystis jirovecii pneumonia: A challenging case. Am J Case
Rep. 21(e919570)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Celesia BM, Marino A, Del Vecchio RF,
Bruno R, Palermo F, Gussio M, Nunnari G and Cacopardo B: Is it safe
and cost saving to defer the CD4+ cell count monitoring
in stable patients on ART with more than 350 or 500 cells/µl?
Mediterr J Hematol Infect Dis. 11(e2019063)2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Marino A, Zafarana G, Ceccarelli M,
Cosentino F, Moscatt V, Bruno G, Bruno R, Benanti F, Cacopardo B
and Celesia BM: Immunological and clinical impact of DAA-mediated
HCV eradication in a cohort of HIV/HCV Coinfected patients:
Monocentric Italian experience. Diagnostics.
11(2336)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Micali C, Russotto Y, Caci G, Ceccarelli
M, Marino A, Celesia BM, Pellicanò GF, Nunnari G and Venanzi Rullo
E: Loco-regional treatments for hepatocellular carcinoma in people
living with HIV. Infect Dis Rep. 14:43–55. 2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Marino A, Scuderi D, Locatelli ME, Gentile
A, Pampaloni A, Cosentino F, Ceccarelli M, Celesia BM, Benanti F,
Nunnari G, et al: Modification of serum brain-derived neurotrophic
factor levels following anti-HCV therapy with direct antiviral
agents: A new marker of neurocognitive disorders. Hepat Mon.
20(e95101)2020.
|
|
31
|
Burgaletto C, Brunetti O, Munafò A,
Bernardini R, Silvestris N, Cantarella G and Argentiero A: Lights
and shadows on managing immune checkpoint inhibitors in oncology
during the COVID-19 Era. Cancers. 13(1906)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Marino A, Munafò A, Zagami A, Ceccarelli
M, Di Mauro R, Cantarella G, Bernardini R, Nunnari G and Cacopardo
B: Ampicillin plus ceftriaxone regimen against Enterococcus
faecalis endocarditis: A literature review. J Clin Med.
10(4594)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Erdem H, Hargreaves S, Ankarali H,
Caskurlu H, Ceviker SA, Bahar-Kacmaz A, Meric-Koc M, Altindis M,
Yildiz-Kirazaldi Y, Kizilates F, et al: Managing adult patients
with infectious diseases in emergency departments: International
ID-IRI study. J Chemother. 33:302–318. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
El-Sokkary R, Uysal S, Erdem H, Kullar R,
Pekok AU, Amer F, Grgić S, Carevic B, El-Kholy A, Liskova A, et al:
Profiles of multidrug-resistant organisms among patients with
bacteremia in intensive care units: An international ID-IRI survey.
Eur J Clin Microbiol Infect Dis. 40:2323–2334. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
RECOVERY Collaborative Group. Tocilizumab
in patients admitted to hospital with COVID-19 (RECOVERY): A
randomised, controlled, open-label, platform trial. Lancet.
397:1637–1645. 2021.PubMed/NCBI View Article : Google Scholar
|
